Alaunos Therapeutics winds down TCR-T trial, cuts workforce 60%, explores strategic alternatives

Alaunos Therapeutics, Inc.

Q2 2023 net loss $8.8M ($0.04 per share); cash $18.3M, expected to fund ops into Q4 2023.
Wind-down of TCR-T Library Phase 1/2 trial; 83% disease control rate in 6 evaluable patients.
Workforce reduction of ~60%; retains key hunTR platform R&D capabilities.
Engaged Cantor Fitzgerald to explore strategic alternatives including sale, merger, or partnerships.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alaunos Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $8.8 million, or $(0.04) per share, EPS $(0.04) per share.

Period: the second quarter ended June 30, 2023
Net income: Net loss was $8.8 million, or $(0.04) per share
EPS: $(0.04) per share
Result: reported results

Exact text from the filing

On August 14, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the three and six months ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-212358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.